Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Celgene will pay $225 million up front and make a $36 million equity investment to collaborate with Jounce Therapeutics, a three-year-old company focused on cancer immunotherapies and predictive biomarkers. In return, Celgene will have options on Jounce’s lead product candidate, JTX-2011, and up to four early-stage programs. Expected to soon enter clinical trials, JTX-2011 is an antibody that activates a T-cell surface protein believed to stimulate an anticancer immune response. Jounce could earn up to $2.3 billion in milestone payments across all the programs.
This article has been sent to the following recipient: